- Renewed takeover speculation around Pfizer fuels interest in $VKTX
- Novo Nordisk ($NVO) is also considered a potential candidate after the MTSR takeover went to Pfizer
- Canaccord Genuity raises the price target slightly to $107 (from $106) and confirms Buy - around +161 % upside potential at the current price of $41
- Stifel (Buy, $40.60) after CEO and CFO appearance: Recruiting in VANQUISH program running at record pace, full enrollment by Q1 2026 expected - Several paths to commercialization in sight
- Valuation more favorable than $MTSR, Pipeline is considered stronger and more advanced